

## CONTINUING MEDICAL EDUCATION

## Improving lymphoma outcome through expanding access to immunotherapy – 63985-59273

Date: May 1, 2024

Time: 5:00 PM-6:00 PM

Rainbow Amphitheater

*Changchun Deng, MD, PhD*  
*University Hospitals Cleveland Medical Center*

### Educational Objectives

At the conclusion of this activity, the participant should be better able to:

- 1 Explain heterogeneity of lymphoma
- 2 List currently available CAR-T products
- 3 Discuss SCC clinical trials leveraging the power of immunotherapy

### Accreditation and Credit Designation Statements

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Disclosures:

All relevant financial relationships have been mitigated. This activity's planners and speaker(s) have made the following disclosures:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Quintin Pan, PhD	Co-Director	Nothing to disclose - 04/09/2024
Brett E Glotzbecker, MD	Co-Director	Nothing to disclose - 08/31/2023
Chris Wong Ciepiel, MD	Co-Director	Nothing to disclose - 08/30/2023
Changchun Deng, MD, PhD	Faculty	Nothing to disclose - 04/26/2024